PFDN2 Antibody

What is the biological role of PFDN2 and why is it important to study?

PFDN2 functions as one of six subunits in the prefoldin complex, which acts as a molecular chaperone essential for proper protein folding. It specifically binds to nascent polypeptide chains and promotes folding in cellular environments where multiple competing pathways exist for nonnative proteins . The prefoldin complex binds specifically to cytosolic chaperonin (c-CPN) and transfers target proteins to it, preventing protein aggregation and ensuring proper folding of critical proteins including cytoskeletal components.

Beyond its chaperone function, PFDN2 has recently been implicated in:

• Cell cycle regulation through the hnRNPD-MYBL2 axis

• Potential role in autoimmunity associated with Type 2 Diabetes

• Cancer progression, particularly in gastric cancer

These emerging roles make PFDN2 an important protein to study for understanding both fundamental cellular processes and disease mechanisms.

What applications are PFDN2 antibodies suitable for?

PFDN2 antibodies have been validated for multiple experimental applications:

When selecting applications, consider your research question carefully. For protein expression studies, Western blot provides quantitative information about PFDN2 levels. For determining cellular localization, ICC/IF is preferable. For analyzing tissue expression patterns, IHC offers valuable spatial information.

What are the key considerations for validating PFDN2 antibodies?

Proper validation is critical for obtaining reliable results with PFDN2 antibodies:

• Predicted molecular weight verification: PFDN2 has a calculated molecular weight of 16.6-17 kDa, though observed bands may appear at 17-20 kDa due to post-translational modifications .

• Knockdown/knockout validation: Compare signal between wild-type samples and those with PFDN2 knockdown using siRNA or CRISPR-Cas9 approaches .

• Positive controls: Use cell lines known to express PFDN2, such as HEK-293T, L02, or Neuro-2a cells .

• Cross-validation: Compare results with multiple antibodies targeting different PFDN2 epitopes to confirm specificity.

• Application-specific validation: For IHC, test different antigen retrieval methods (TE buffer pH 9.0 or citrate buffer pH 6.0) ; for ICC/IF, optimize fixation and permeabilization conditions.

These validation steps ensure that observed signals genuinely represent PFDN2 and not non-specific binding or artifacts.

How is PFDN2 implicated in Type 2 Diabetes and what methodologies can be used to study this connection?

A significant association between anti-PFDN2 autoantibodies and Type 2 Diabetes Mellitus (T2DM) has been established:

To study this association, researchers should consider these methodological approaches:

• Microsphere-based immunoassays: For detecting anti-PFDN2 autoantibodies in patient plasma samples.

• Statistical considerations: Adjust for sample storage time, background MFI, and important covariates including age, BMI, sex, and genetic factors.

• Sample selection: Focus on early-onset T2DM cases with short disease duration (<5 years) to capture autoantibodies before potential decline with disease progression.

• Controls: Include both age-matched controls with normal glucose regulation and disease controls to establish specificity of the autoantibody association.

This research suggests autoimmunity may play an important role in T2DM pathogenesis, with anti-PFDN2 antibodies potentially serving as useful biomarkers, particularly for young-onset disease .

What is the role of PFDN2 in cancer progression and what techniques can elucidate its mechanisms?

Recent research has identified PFDN2 as having significant oncogenic potential, particularly in gastric cancer:

To investigate PFDN2's role in cancer, consider these methodological approaches:

• Expression analysis: Compare PFDN2 expression in tumor vs. normal tissues using qRT-PCR, Western blot, and IHC with carefully validated antibodies.

• Functional studies: Use siRNA knockdown and lentiviral overexpression systems to modulate PFDN2 levels and assess effects on proliferation, migration, and invasion.

• Cell cycle analysis: Employ flow cytometry and EdU incorporation assays to quantify cell cycle distribution changes following PFDN2 manipulation.

• Protein interaction studies: Use co-immunoprecipitation with PFDN2 antibodies followed by mass spectrometry to identify binding partners.

• Transcriptome analysis: Perform RNA sequencing after PFDN2 knockdown to identify downstream effectors.

These findings suggest PFDN2 may serve as both a prognostic biomarker and potential therapeutic target in gastric cancer .

How does PFDN2 regulate the cell cycle through the hnRNPD-MYBL2 axis?

PFDN2 has been found to regulate cell cycle progression through a specific molecular pathway:

The mechanism involves several steps:

• PFDN2 binds to hnRNPD as demonstrated by co-immunoprecipitation experiments.

• This interaction facilitates nuclear translocation of hnRNPD, as confirmed by immunofluorescence showing increased nuclear colocalization.

• Nuclear hnRNPD regulates MYBL2 expression.

• MYBL2 activates transcription of cell cycle progression genes including cyclins and CDKs.

• These downstream effectors drive G1/S phase transition and promote cancer cell proliferation.

Rescue experiments provided critical evidence for this pathway, as MYBL2 knockdown reversed the effects of PFDN2 overexpression, and MYBL2 overexpression rescued the phenotype of PFDN2 knockdown cells .

For studying this pathway, researchers should consider combinatorial approaches targeting multiple components simultaneously to fully elucidate the mechanism.

What are the optimal conditions for using PFDN2 antibodies across different applications?

Successful experiments with PFDN2 antibodies require careful optimization:

For Western blot:

• Expected band size: 17-20 kDa

• Positive controls: HEK-293T, L02, or Neuro-2a cell lysates

• Loading control: GAPDH or β-actin

• Transfer time: Optimize for small proteins (shorter times, lower voltage)

For IHC:

• Human pancreas, lung cancer, and liver cancer tissues have been validated as positive controls

• Background reduction: Increase blocking time (5% BSA or 10% normal serum)

• Counterstaining: Hematoxylin works well for nuclear contrast

For ICC/IF:

• L02 cells serve as good positive controls

• Signal amplification: Consider tyramide signal amplification for weak signals

• Confocal imaging: Recommended for detailed subcellular localization studies

Always perform antibody titration experiments when using a new PFDN2 antibody to determine optimal concentration for your specific application and sample type.

How can researchers troubleshoot common issues with PFDN2 antibody experiments?

When experiments with PFDN2 antibodies yield suboptimal results, consider these troubleshooting approaches:

For PFDN2 specifically:

• Size issues: As a small protein (17 kDa), PFDN2 can be lost during transfer or masked by abundant proteins. Consider gradient gels (4-20%) for better resolution.

• Subcellular localization: While primarily cytoplasmic, PFDN2 interactions with nuclear proteins like hnRNPD suggest it may shuttle between compartments. Use subcellular fractionation to confirm localization patterns.

• Species reactivity: Verify the antibody's reactivity with your species of interest. Some PFDN2 antibodies are validated for human and mouse samples but may have variable reactivity with other species .

• Epitope accessibility: Different antibodies target different PFDN2 epitopes. If one antibody fails, try another targeting a different region.

• Quantification challenges: For quantitative Western blot analysis, use a standard curve of recombinant PFDN2 protein to ensure accurate measurements.

How can PFDN2 antibodies be used in clinical research settings?

PFDN2 antibodies have several applications in clinical research:

For clinical research applications, critical considerations include:

• Standardization: Use validated antibodies with established protocols to ensure reproducibility across patient samples.

• Scoring systems: Develop and validate quantitative scoring systems for PFDN2 IHC (e.g., H-score, Allred score) to enable consistent assessment across samples.

• Reference standards: Include positive and negative controls in each batch to account for technical variation.

• Correlation with outcomes: Design studies to correlate PFDN2 expression with clinical outcomes, treatment response, and patient survival.

The association between anti-PFDN2 antibodies and Type 2 Diabetes illustrates potential utility as a biomarker for autoimmune components of metabolic disease, particularly in younger patients (20-39 years) , which could inform personalized treatment approaches.

What methodological approaches can detect anti-PFDN2 autoantibodies in Type 2 Diabetes research?

For studying anti-PFDN2 autoantibodies in Type 2 Diabetes, researchers have employed specific methodological approaches:

To implement this methodology:

• Sample selection: In the key study, researchers examined 476 T2DM cases and 424 controls, focusing on cases with disease duration <5 years .

• Power calculation: Sample size was calculated to achieve 90% power with an alpha of 0.001 .

• Covariates: Account for age, sex, BMI, and genetic factors (e.g., HLA haplotypes) in statistical models .

• Age stratification: Analyze results by age groups, as the association was strongest among younger patients (20-39 years) .

This approach revealed that 10.5% of T2DM patients aged 20-29 years were anti-PFDN2 antibody positive compared to 3.2% of age-matched controls (p=0.03) , supporting the potential utility of this biomarker in identifying patients with autoimmune components to their T2DM.

How can researchers design experiments to investigate PFDN2's role in cancer progression?

To effectively study PFDN2's role in cancer:

A comprehensive research design should include:

• Clinical correlation: Compare PFDN2 expression with patient survival and clinical parameters using Kaplan-Meier analysis and Cox regression .

• Functional validation: Perform rescue experiments by manipulating downstream targets (e.g., MYBL2) to confirm mechanistic relationships .

• In vivo models: Use xenograft models with PFDN2 knockdown or overexpression to assess tumor growth and metastatic potential.

• Therapeutic potential: Test whether PFDN2 inhibition sensitizes cancer cells to standard chemotherapies.

This approach has successfully demonstrated that PFDN2 promotes gastric cancer progression via the hnRNPD-MYBL2 axis , suggesting its potential as both a biomarker and therapeutic target.

What emerging techniques could enhance PFDN2 research?

Several cutting-edge approaches could advance PFDN2 research:

These approaches could help address outstanding questions about PFDN2, including:

• Does PFDN2 have chaperone-independent functions beyond its role in the prefoldin complex?

• How does PFDN2 contribute to specific pathways in different cancer types?

• What is the structural basis for PFDN2's interaction with hnRNPD and how does this facilitate nuclear translocation?

• Could anti-PFDN2 autoantibodies be pathogenic in T2DM or merely biomarkers?

• Are there tissue-specific client proteins that particularly depend on PFDN2 for proper folding?

As technology advances, our understanding of PFDN2's multifaceted roles in normal physiology and disease will likely expand significantly.

How might PFDN2 research translate to clinical applications?

PFDN2 research has several potential clinical applications:

Translational research priorities should include:

• Biomarker validation: Confirm the utility of anti-PFDN2 antibodies for identifying patients with autoimmune components to T2DM in diverse populations.

• Intervention studies: Determine if patients with elevated anti-PFDN2 antibodies respond differently to specific diabetes treatments, particularly immunomodulatory approaches.

• Drug development: Screen for compounds that disrupt the PFDN2-hnRNPD interaction as potential cancer therapeutics.

• Combination approaches: Test whether PFDN2 inhibition synergizes with cell cycle-targeting drugs in cancer treatment.

The association between PFDN2 and both metabolic and neoplastic diseases highlights its potential importance in precision medicine approaches that target specific molecular pathways in individual patients.